Furthermore, the observed reductions in hospitalizations and mortality, along with improvements in functional capacity and quality of life, suggest that acoramidis may offer benefit to both variant ...

BridgeBio Pharma emphasizes the potential for serum TTR levels to serve as a prognostic biomarker in ATTR-CM, aiding in treatment decisions and patient care. The company, which specializes in ...

More information: Ofir Shorer et al, Single-cell meta-analysis of T cells reveals clonal dynamics of response to checkpoint immunotherapy, Cell Genomics (2025). DOI: 10.1016/j.xgen.2025.100842 ...

Alnylam CEO Yvonne Greenstreet, M.D., said there is plenty of room for new options for ATTR-CM patients. “We really are in a category growth story,” Greenstreet said.

Acoramidis is a selective small molecule, orally administered near-complete (=90%) transthyretin (TTR) stabilizer. ATTR-CM is a progressive fatal disease that presents as an infiltrative, restrictive ...

XGen Network (XGN), a specialist in 5G Broadcast solutions, announced at the LPTV Broadcasters Association’s conference the development of its LPTV Broadcast Positioning System (BPS) leveraging 5G ...

Here’s how it works. LAS VEGAS—During the LPTV Broadcasters Association's conference being held at the 2025 NAB Show, XGen Network (XGN) announced the development of its LPTV Broadcast Positioning ...

March 25, 2025 – The FDA has approved a new treatment for adults with a life-threatening heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is a rare but serious ...

Also, Alnylam wins an important approval for ATTR-CM. The FDA has approved Alynylam’s RNAi therapy Amvuttra for treating transthyretin amyloid cardiomyopathy (ATTR-CM), positioning it to ...

These fibrils form the amyloid protein, which is associated with CV damage and premature mortality in patients with ATTR-CM. The approval is based on the results of the phase 3, double-blind ...

Two out of every five patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with tafamidis (Vyndamax and Vyndaqel; Pfizer) can be expected to die in less than 4 years, new real-world ...

A demonstration group advocating for the exclusion of Kurds in Japan, left, and citizens counter-protesting against them are seen in front of JR Warabi Station in Warabi, Saitama Prefecture, on ...